Travere Therapeutics (TVTX) Cash & Current Investments (2016 - 2025)
Historic Cash & Current Investments for Travere Therapeutics (TVTX) over the last 16 years, with Q3 2025 value amounting to $110.9 million.
- Travere Therapeutics' Cash & Current Investments rose 20467.74% to $110.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.9 million, marking a year-over-year increase of 20467.74%. This contributed to the annual value of $58.5 million for FY2024, which is 61.71% up from last year.
- Latest data reveals that Travere Therapeutics reported Cash & Current Investments of $110.9 million as of Q3 2025, which was up 20467.74% from $75.2 million recorded in Q2 2025.
- Over the past 5 years, Travere Therapeutics' Cash & Current Investments peaked at $256.6 million during Q1 2022, and registered a low of $32.3 million during Q2 2024.
- Over the past 5 years, Travere Therapeutics' median Cash & Current Investments value was $83.3 million (recorded in 2021), while the average stood at $107.9 million.
- As far as peak fluctuations go, Travere Therapeutics' Cash & Current Investments crashed by 7475.87% in 2024, and later skyrocketed by 20467.74% in 2025.
- Travere Therapeutics' Cash & Current Investments (Quarter) stood at $165.8 million in 2021, then plummeted by 62.78% to $61.7 million in 2022, then fell by 5.69% to $58.2 million in 2023, then grew by 0.62% to $58.5 million in 2024, then surged by 89.51% to $110.9 million in 2025.
- Its Cash & Current Investments was $110.9 million in Q3 2025, compared to $75.2 million in Q2 2025 and $61.9 million in Q1 2025.